Why Collaborate With Us?

State-of-the-Art Infrastructure

powering advanced research and innovation.

Collaborative Knowledge

enabling seamless information exchange and discovery.

Expert Research Access

connecting to specialised scientific expertise.

Breakthrough Innovations

accelerating drug development and addressing unmet medical needs.

Over Two Decades of Expertise

in Biologics.

Areas of Interest

External Collaborations

Partnering with global innovators to enhance Biologics R&D, from optimised mAb expression systems to advanced drug delivery and toxicity testing.

Academic Collaborations

Engaging with top institutes through PhD programmes and research partnerships to drive scientific advancements in Biologics.

How We Collaborate

Some scopes that the various teams at Dr. Reddy’s Biologics have explored are presented here. We truly believe that scientific collaborations are key to solving problems and, hence, are open to scientific collaboration opportunities in the space of Biosimilars.

External Collaborations

Scope

Optimized Productivity Platforms for Monoclonal Antibodies (mAb)

Advancing high-yield expression systems to enhance manufacturing efficiency and scalability.

Cost-Effective Cell Culture Media Development

Innovative formulations to reduce costs while significantly increasing specific productivity .

External Collaborators

Cytiva
(Hyclone, USA)
Merck
(Millipore/SAFC, USA)
ThermoFisher
(USA)

Academic Collaborations

MoUs with leading institutes for PhD programmes

BITS Pilani Hyderabad
Mahindra University
(Hyderabad, India)

Internal Business Units Collaborations

IPDO

IPDO

Business Unit


Scope

Proof-of-concept (POC) studies for antibody-drug conjugate product

AURIGENE-LOGO

Aurigene Pharmaceutical Services Ltd (APSL)

Business Unit/Subsidiaries of Dr.Reddys

 

Scope

Process development for new bispecific molecules

AURIGENE-Oncology

Aurigene Oncology Limited (AOL)

Business Unit/Subsidiaries of Dr.Reddys

 

Scope

Driving discovery of New Biological Entities (NBEs)

DRILS

DRILS

Business Unit/Subsidiaries of Dr.Reddys

 

Scope

Scientific collaborations for mRNA POC activities

0/40
0/40
0/250

Discover Biologics

With seven commercially available and internationally marketed products, and over 10 formulations in the pipeline, we demonstrate our care through scientific breakthroughs.

Our News, Stories, and Insights

  • News
  • 21-05-2024

Alvotech and Dr. Reddy’s enter into collaboration for its biosimilar to treat osteoporosis

  • News
  • 21-05-2024

Dr. Reddy's Secures Rights For Denosumab In US, Europe And UK

  • News
  • 22-03-2024

Dr. Reddy’s intros Avastin biosimilar in the U.K.

  • News
  • 20-03-2024

Dr. Reddy's Launches Cancer Drug Versavo in the UK

Bricks of Biologics, appreciates the contribution and celebrates our people who are the building blocks of Dr. Reddy's Biologics.

 

Bricks of biologics in general refers to bio-bricks as genetic building blocks which are DNA sequences that can be assembled to create complex biological systems.